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A practical approach for assessing chemosensitivity in 
colorectal cancer cell lines by comparative analysis of 
cell viability and thymidylate synthase mRNA 
expression
Hyun Yong Hwang
Department of Laboratory Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
Purpose: The purpose of this study is to suggest a probable problem in chemosensitivity tests performed in practice and to 
speculate on practicable measures for more accurate chemosensitivity evaluation. Methods: Three colorectal cancer cells 
(RSC, RRC1, and RRC2) were treated with 5-fluorouracil (5-FU). Inhibition percentage (%inhibition) of cancer cells and rela-
tive quantitation of thymidylate synthase (TS) mRNA were measured on day 2, day 5 after replacement of 70% media on day 
2, day 7, and day 3 after replacement of all media on day 7. Doses that produced 50% inhibition (Dm) were calculated to eval-
uate drug effect. Relative quantitation of TS mRNA and correlations between TS mRNA levels and 5-FU concentrations were 
analyzed. Results: RRC1 was more resistant than RRC2 on day 7, but Dm value of RRC2 increased three days after replace-
ment of media from 12.3 to 18.1. Mean TS mRNA levels of RSC on D2 and D7 were significantly lower than those of RRC1 
and RRC2, respectively (P = 0.004, P = 0.004 on D2; P = 0.010, P = 0.006 on D7). TS mRNA levels in RRC1 were significantly re-
versely correlated with 5-FU concentrations on day 2 (correlation coefficient = －0.867, P = 0.015). On the other hand, correla-
tions were not significant in RRC2 (r = 0.067). Conclusion: Evaluating %inhibition of cancer cells at one point in chemo-
sensitivity tests seems to be inadequate in determining chemotherapeutic regimens. Multilateral approaches, such as trials 
evaluating cancer cell survival before and after media replacement and correlations between TS mRNA levels and 5-FU con-
centrations, needs to be implemented for the practical application of chemosensitivity tests.
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INTRODUCTION
When chemosensitivity testing is performed for chemo-
therapy in patients, the interpretation of it is usually done 
on day 2 to 7 after test [1-5]. This is just considering in-
hibition percentage (%inhibition) of cancer cells at one 
point in the lifetime of the cancer cells; however, the in-
hibition rates of cancer cells in vivo may differ depending 
on the characteristics of the cancer cell, which might cause 
some unexpected results in practice. If unexpected behav-Practical approach for chemosensitivity
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Fig. 1. Amplification curve of realtime quantitative polymerase chain reaction (PCR) for thymidylate synthase (TS) mRNA and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). FAM dye and JOE dye were used for TS mRNA and GAPDH, respectively. One cycle 
of reverse transcription (stage 1, 42
oC 5 minutes; stage 2, 95
oC 10 seconds) and 40 cycles of PCR reaction (stage 3, 95
oC 5 seconds; 60
oC 30 
seconds) were performed for real-time quantitative PCR. Blue lines and yellow lines indicate TS mRNA and GAPDH, respectively. All tested
extracted RNAs were drawn in the figure together. 
iors relating to genetic characteristics are observed in can-
cer cells after chemosensitivity tests have been completed, 
it might be dangerous to treat patients according to the re-
sults of the test. Here, the author intends to suggest a likely 
problem in chemosensitivity testing performed in practice 
and speculates on practicable measures for more accurate 
chemosensitivity evaluation.
METHODS
Cancer cell and chemical
Three kinds of cancer cells (RSC, RRC1, and RRC2) were 
derived from SNU-C2A and SNU-C1 colorectal cancer cell 
lines purchased from the Korean cell line bank. The cancer 
cells were cultured in Dulbecco's Modified Eagle’s Medi-
um (Invitrogen, Carlsbad, CA, USA) containing 10% fetal 
bovine serum (Invitrogen), 50,000 U/L penicillin (Invitro-
gen), 80 μM streptomycin (Invitrogen), and 0.25 μg ampho-
tericin B (Invitrogen) in a humidified incubator (Sanyo, 
Gunma, Japan) at 37
oC with an atmosphere of 10% CO2. 
5-fluorouracil (5-FU) was used as a cancer drug. 50 μg/mL 
was used as 100% treatment dose of 5-FU. 
Culture and treatment
Cancer cells were cultured in 96-well plates for chemo-
sensitivity and 6-well plates for mRNA quantitation. Can-
cer cells were treated with serially diluted 5-FU from 0 (no 
drug) to 200% treatment dose. Each cancer cell line was 
plated in a 96-well plate at a density of 5 × 10
3 cells/well and 
in a 6-well plate at a density of 8 × 10
4 cells/well, respec-
tively. Negative control (no cell) was also included in each 
evaluation plate. Inhibition percentage of cancer cell and 
relative quantitation of thymidylate synthase (TS) mRNA 
were measured in each 96-well plate and 6-well plate on 
day 2 (D2), day 5 after 70% media replacement on day 2 
(D2＋5), day 7 (D7), and day 3 after 100% media replace-
ment on day 7 (D7＋3), respectively. Here, media replace-
ment was intended to induce regrowth of cancer cells. 
Chemosensitivity evaluation
The effect of the drug on cell viability was tested using 
a CellTiter 96 Aqueous non-radioactive cell proliferation 
assay kit (Promega Co., Madison, WI, USA). After incubat-
ing the test plate with reagents of the assay kit for 2 hours 
at 37°C in a humidified 5% CO2 atmosphere, absorbance at 
490 nm was measured using a microplate reader. Tests 
were repeated three times, and the means of the test results 
were used for analyses. Inhibition percentage of cancer 
cell line was calculated using the following equations:
T/C = Absorbance of cultured cancer cell treated with 
5-FU / Absorbance of cultured cancer cell not 
treated with 5-FU
%inhibition of cancer cell = (1－T/C) × 100 [6]Hyun Yong Hwang
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Fig. 2. Dose-effect curve on each evaluation day. Shown are dose-effect curve on D2 and D2＋5 (A) and D7and D7＋3 (B) in each cancer cell 
line. D2, day 2; D2＋5, day 5 after 70% media replacementon day 2; D7, day 7; D7＋3, day 3 after 100% media replacement on day 7.
Table 1. Dm values and mean values of TS mRNA in each cancer 
cell
Evaluation 
day
Cell Dm value TS mRNA mean (SD)
D2 RSC 60.6 0.65 (0.20)
RRC1 415.7 2.60 (0.71)
RRC2 90.0 2.45 (0.24)
D2＋5 RSC 5.8 1.36 (1.55)
RRC1 17.1 2.87 (0.20)
RRC2 18.3 2.92 (0.24)
D7 RSC 2.3 1.27 (0.34)
RRC1 20.7 2.71 (0.34)
RRC2 12.3 2.77 (0.41)
D7＋3 RSC 1.8 5.62 (7.24)
RRC1 7.0 2.98 (0.61)
RRC2 18.1 2.97 (0.22)
Dm, median-effect dose; TS, thymidylate synthase. D2, day 2; D2＋
5, day 5 after 70% media replacement on day 2; D7, day 7; D7＋3, 
day 3 after 100% media replacement on day 7.
Median-effect dose (Dm), the dose that produces 50% 
effect, was calculated with CalcuSyn (Biosoft, Cambridge, 
UK).
Relative quantitation of TS mRNA
RNA was extracted from cancer cell using the Absolute-
ly RNA Microprep kit (Stratagene, La Jolla, CA, USA). 
Quantitative real-time polymerase chain reaction (PCR) 
was performed with the One Step PrimeScript RT-PCR kit 
(Takara Bio Inc., Shiga, Japan); transcription of cDNA and 
quantitation of TS mRNA with TaqMan TS mRNA gene 
expression assay kit (Applied Biosystems, Foster City, CA, 
USA) were performed in the ABI prism 7700 (Applied 
Biosystems). TaqMan glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (Applied Biosystems) was used as an 
internal control. Relative quantitation of TS mRNA was 
calculated with TS mRNA and GAPDH (Fig. 1).
Statistical analysis
TS mRNA levels in each cancer cell on four evaluation 
days were compared by Mann-Whitney U test. To analyze 
the difference of TS mRNA quantitation according to the 
change of 5-FU concentration on each evaluation day, the 
correlation between TS mRNA level and 5-FU concen-
tration was evaluated with Kendall’s tau-b. Statistical sig-
nificance was established at the P ＜ 0.05 level for each 
analysis.
RESULTS
Chemosensitivity evaluation
RSC was the most sensitive on all evaluation days (Table 
1, Fig. 2). RRC1 was the most resistant against 5-FU on D2 
and D7. Dm values of RRC1 were 6.9 times and 4.6 times 
higher than RSC and RRC2 on D2, respectively, and those 
of RRC1 on D7 were 9 times and 1.7 times higher than RSC 
and RRC2 on D7, respectively. RRC2 was the most resistant 
on D2＋5 and D7＋3. Dm values of RRC2 were 3.1 times Practical approach for chemosensitivity
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Table 2. Change of Dm values after media replacement 
Change of Dm value after media replacement (%)
D2 vs. D2＋5D 7  v s .  D 7 ＋3
RSC 9.6↓
a) 78.3↓
RRC1 4.1↓ 33.8↓
RRC2 20.3↓ 147.2↑
b)
Dm, median-effect dos; D2, day 2; D2＋5, day 5 after 70% media 
replacement on day 2; D7, day 7; D7＋3, day 3 after 100% media 
replacement on day 7.
a)Decrease. 
b)Increase.
Fig. 3. Relative quantitation of thymidylate synthase (TS) mRNA in serially diluted 5-fluorouracil (5-FU) concentrations. Correlations 
between TS mRNA levels and 5-FU concentrations were evaluated with Kendall’s tau-b on D2 (A), D2＋5 (B), D7 (C), and D7＋3 (D). D2, day
2; D2＋5, day 5 after 70% media replacement on day 2; D7, day 7; D7＋3,day 3 after 100% media replacement on day 7.
and 1.1 times higher than RSC and RRC1 on D2＋5, respec-
tively, and those of RRC2 on D7＋3 were 10.1 times and 2.6 
times higher than RSC and RRC1 on D7＋3, respectively. 
Dm values on D2 decreased after media replacement on 
D2＋5 (9.6%, 4.1%, and 20.3% in RSC, RRC1, and RRC2, re-
spectively). Dm values on D7 decreased after media re-
placement on D7＋3 (78.3% and 33.8% in RSC, RRC1, re-
spectively), on the other hand, Dm value on D7 increased 
in RRC2 after media replacement on D7＋3 (147.2%) 
(Table 2).
Relative quantitation of TS mRNA
Mean TS mRNA levels in RSC in tested 5-FU concen-
trations were lower than those of RRC1 and RRC2 on D2, 
D2＋5, and D7; however, TS mRNA  value of RSC was 
higher than those of RRC1 and RRC2 on D7 (Table 1). 
Mean TS mRNA levels of RSC on D2 and D7 were sig-
nificantly lower than those of RRC1 and RRC2, re-
spectively (P = 0.004, P = 0.004 on D2; P = 0.010, P = 0.006 on 
D7).Hyun Yong Hwang
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Correlation between TS mRNA values and 5-FU 
concentrations
TS mRNA levels in RRC1 were significantly reversely 
correlated with 5-FU concentrations on D2 (correlation co-
efficient, r = －0.867). On the other hand, correlations were 
not significant in RRC2 (r = 0.067) (Fig. 3). Those correla-
tions in RSC were not as strong on D2 (r = 0.600) but sig-
nificantly strong on D7 and D7＋3 (r = 0.867, r = 1.000, re-
spectively).
DISCUSSION
In Table 1 and Fig. 2, chemosensitivity against 5-FU on 
D7 indicated that RSC was the most sensitive and RRC1 
was the most resistant among tested cancer cells. RRC1 is 
more resistant to 5-FU than RRC2 on D7, but %inhibition 
in RRC1 and RRC2 showed some changes on D7＋3. Dm 
value increased from 12.3 to 18.1 in RRC2 while decreasing 
continuously in RRC1 (Tables 1, 2). If the chemosensitivity 
is decided on D7, RRC1 is definitely the most resistant 
among tested cancer cells in this study. However, the most 
resistant to 5-FU is RRC2 on D7＋3. If this happens in pa-
tients, it would be difficult to decide whether or not to ac-
cept the results of chemosensitivity on D7. This also raises 
the question of whether the chemosensitivity test measur-
ing %inhibition of cancer cells at one point of their lifetime 
could completely guarantee the destination of cancer cells 
after chemotherapy in vitro. 
Here, the author evaluated %inhibition of cancer cells 
before and after media replacement intended to help re-
growth of cancer cells after chemotherapy. This was also 
an attempt to make a cultural environment closer in sim-
ilarity to in vivo status, because less damaged cancer cells 
would normally obtain enough nutrients from the body 
after the direct effects of chemotherapy ended. As a result, 
evaluating %inhibition of cancer cells before and after me-
dia replacement seemed to be helpful to better differ-
entiate between sensitive and resistant cancer cells in this 
study.
When 5-FU is administered to patients, its metabolite, 
5-fluoro-2’-deoxyuridine-5’-monophosphate, binds to TS 
involved in DNA synthesis [7-9]. Significant relations be-
tween TS levels and 5-FU sensitivity have been reported 
[10,11]. Although the correlation between TS mRNA and 
protein expression is not always significant [12], TS 
mRNA levels are known to be higher in the 5-FU resistant 
cancer group compared to the 5-FU sensitive group 
[13-15]. 
In Table 1, mean values of TS mRNA in RSC on D2 and 
D7 showed significantly low values compared to those in 
RRC1 and RRC2, respectively (P = 0.004, P = 0.004 on D2; P 
= 0.010, P = 0.006 on D7). On D2＋5 and D7＋3, relative 
quantitations of TS mRNA at 100 and 200% treatment dose 
of 5-FU in RSC were very high compared to those at other 
concentrations. After all, these increased levels are thou-
ght to make it difficult to differentiate between RSC and 
RRC1 or between RSC and RRC2 on D2＋5 and D7＋3. 
TS levels as determined by enzyme activity assays, im-
munohistochemistry and mRNA expression were repor-
ted to be initially decreased by 5-FU treatment, which 
were followed by induction of TS [16]. When patients with 
colorectal cancer were given one presurgery bolus of 5-FU, 
TS mRNA expressions in primary cancer cells of exposed 
patients were higher than in those of unexposed patients 
[17]. These studies indicate that 5-FU exposure can affect 
TS mRNA expression levels in cancer cells. However, the 
correlations between TS mRNA levels and 5-FU concen-
trations are not well known. 
In Fig. 3, significant correlation between TS mRNA lev-
els in RRC1 and 5-FU concentrations were observed on D2 
(correlation coefficient, r = －0.867), but such significant 
correlations were not found in RRC2 (r = 0.067) (Fig. 3). 
And those correlations in RSC were also significantly 
strong on D7 and D7＋3 (r =0.867, r = 1.000, respectively). 
Correlations between TS mRNA values and 5-FU concen-
trations, as well as mean values of TS mRNA in Table 1, 
combine to be able to differentiate among RSC, RRC1, and 
RRC2 in this study. Although TS enzyme activity was not 
measured in this study, changes in TS mRNA expression 
levels to 5-FU concentrations seem to affect the response of 
cancer cells against 5-FU treatment.
Each cancer cell has its own genetic characteristic re-
ported to cause different responses against the same che-
motherapeutic environment [18-20]. And chemotherapy 
itself is a very invasive procedure compared to antibiotics Practical approach for chemosensitivity
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treatment in patients, which makes physicians very care-
ful and sometimes hesitant to treat patients according to 
the chemosensitivity results. Therefore, various approa-
ches to provide more accurate chemosensitivity have to be 
developed for practical application. 
In Korea, two assay methods for chemosensitivity, his-
toculture drug response assay and adenosine triphos-
phate-based chemotherapy response assay are being used 
in practice [4,5]. As previously mentioned, those tests only 
evaluate %inhibition of cancer cell at one point after che-
motherapy, which might not always predict the destina-
tion of cancer cells due to different characteristics of in-
dividual cancer cells. 
Chemosensitivity tests measuring inhibition of cancer 
cells do not evaluate pharmacokinetic and pharmacoge-
netic processes significantly affecting chemosensitivity in 
the body. An integrated approach based on a pharmacoki-
netic analysis combined with dihydropyrimidine dehy-
drogenase genotyping and/or phenotyping has been sug-
gested to be a safer strategy for optimizing the admin-
istration of 5-FU [21]. And a combination of germline TS 
polymorphisms was reported to be an independent prog-
nostic marker in selecting colorectal cancer patients with 
poor prognosis [22]. However, commercially available 
chemosensitivity tests measuring cancer cell survival have 
excluded these pharmacokinetic and pharmacogenetic 
perspectives until now. 
Although more numbers of cases showing conversion 
of Dm values as seen in this study are needed to make con-
clusive results more concrete, evaluating %inhibition of 
cancer cells at one point in a chemosensitivity test seems to 
be insufficient to determine chemotherapeutic regimens. 
Multilateral approaches, such as trials in this study evalu-
ating cancer cell survival before and after media replace-
ment and correlations between TS mRNA levels and 5-FU 
concentrations, need to be implemented for the practical 
application of chemosensitivity testing.
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